Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles

Autor: Jiahong Dong, Xin Lin, Tianxiao Wang, Zhizhong Ren, Yuewei Zhang, Yuanxun Yue, Ying Liu, Xiaowei Yang, Xueqiang Zhao, Zhanqi Wei, Yu Zheng
Rok vydání: 2021
Předmět:
Male
m-TACE
0301 basic medicine
Time Factors
Cirrhosis
Cell
T-Lymphocytes
Regulatory
Gastroenterology
0302 clinical medicine
Immunology and Allergy
Original Research
Drug Carriers
Antibiotics
Antineoplastic
medicine.diagnostic_test
Liver Neoplasms
hepatocellular carcinoma
Middle Aged
Treatment Outcome
medicine.anatomical_structure
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Female
Adult
lcsh:Immunologic diseases. Allergy
medicine.medical_specialty
Carcinoma
Hepatocellular
Immunology
CD4-CD8 Ratio
Immunopotentiator
Flow cytometry
03 medical and health sciences
Immune system
Internal medicine
medicine
Humans
Chemoembolization
Therapeutic
Particle Size
Aged
Epirubicin
business.industry
flow cytometry
medicine.disease
digestive system diseases
BCLC Stage
tumor immunity
030104 developmental biology
Case-Control Studies
lcsh:RC581-607
business
Treg cells
CD8
Zdroj: Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
ISSN: 1664-3224
Popis: ObjectiveTransarterial chemoembolization (TACE) stands for an ideal therapy for patients with intermediate stage HCC. This study was carried out to observe the effect of microparticles-transarterial chemoembolization (microparticles-TACE, m-TACE) on the immune function of hepatocellular carcinoma (HCC) patients by detecting the proportion of regulatory (Treg) cells in the peripheral blood of HCC patients before and after m-TACE, and to determine whether m-TACE has a positive regulatory effect on the immune function of HCC patients.Methods33 HCC patients treated with Gelatn Sponge Microparticles (GSMs-TACE) were enrolled. Flow cytometry was used to determine the proportion of Treg cells and CD4+/CD8+ T cells in peripheral blood of HCC patients 1 day before GSMs-TACE, 1 to 2 weeks and 3 to 5 weeks after GSMs-TACE, respectively.ResultsThe Tregs cell proportion of HCC patients was significantly higher than that of the healthy and cirrhosis controls and was associated with various clinical indicators of HCC patients. The Treg cell proportion in HCC patients with BCLC stage C was higher than that of stage B patients; The Treg cell proportion at 1 to 2 weeks postoperatively was 8.54 ± 1.27%, which was significantly lower than that before the GSMs-TACE. The Treg cell proportion at 3 to 5 weeks postoperatively was 7.59 ± 1.27%, which continued to decline. The ratio of CD4+/CD8+ T cells was 1.31 ± 0.56, 1.86 ± 0.73, 1.76 ± 0.58% (PConclusionThese results indicated that m-TACE could exert a positive regulatory effect on the anticancer immune function of HCC patients, which may be used in combination with immune adjuvant therapies to enhance the efficacy of HCC.
Databáze: OpenAIRE
Externí odkaz: